\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Three clinical programs are advancing and demonstrating the safety and efficacy of onvansertib: Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); Phase 2 study of onvansertib in combination with Zytiga® (abirterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML).

Investor Presentation / Company Overview (button) - May 4, 2020
Recent News
Jan 15, 2021

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in indications with the greatest medical need, including...

Dec 21, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated...

Dec 6, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
January 6, 2021

Fireside Chat with CEOs from five oncology biotech companies designed to explore the increasing but not completely novel trend of conducting clinical trials with new drugs in combination with...

November 23, 2020 - December 3, 2020
September 23, 2020
11:00am - 12:30pm EDT

Cardiff Oncology CEO, Dr. Mark Erlander, and Key Opinion Leaders Afsaneh Barzi, M.D., Ph.D. (City of Hope Comprehensive Cancer Center) and Heinz-Josef Lenz, M.D., FACP (USC Norris Comprehensive Cancer Center) will participate in a discussion featuring the latest data from Cardiff’s Phase 1b/2 clinical trial evaluating onvansertib in combination with FOLFIRI and bevacizumab for the second line treatment of patients with KRAS-mutated metastatic colorectal cancer. A question and answer session will follow the formal presentations.